About H. Hart
Form D filings for RS BioTherapeutics from 2022 to 2024 list H. Hart as executive officer.
H. Hart first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name H. Hart in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people H. Hart works with at each company, as listed on that company's latest Form D.
RS BioTherapeutics Inc. · Form D, Oct 9, 2024
MG
Michael Guzman
Executive officer
CR
Curtis Rhine
Chief Financial Officer
JM
Justin Molignoni
Executive officer and director
DF
David Freas
Director